SCHEMBL6887475

SCHEMBL6887475

CCC(C)c1nc2ccc(N3CCN4CCC3CC4)cc2c(=O)n1CC(=O)NC(C)C

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 4/20 0.42
AVPR1A P37288 16/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890370 0.92 AVPR1B (0.44) AVPR1BAVPR1A
SCHEMBL6887911 0.90 AVPR1B (0.43) AVPR1BAVPR1A
SCHEMBL6889471 0.88 AVPR1B (0.46) AVPR1BAVPR1A
SCHEMBL11920578 0.86 AVPR1B (0.42) AVPR1BAVPR1A
SCHEMBL6886645 0.86 AVPR1B (0.43) AVPR1BAVPR1A
SCHEMBL6891017 0.86 AVPR1B (0.43) AVPR1BAVPR1A
SCHEMBL6887694 0.85 AVPR1B (0.42) AVPR1BAVPR1A
SCHEMBL6890511 0.85 AVPR1B (0.42) AVPR1BAVPR1A
SCHEMBL6889145 0.85 AVPR1A (0.42) AVPR1BAVPR1A
SCHEMBL6888165 0.85 AVPR1B (0.60) AVPR1BAVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 AVPR1B 76/4885AVPR1A 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.